Pathology / Tissue/Cellular Phenotype
~ Phenotype / Expression / Risk Spectrum of HBOC
~ Genetics of Breast & Ovarian Cancer

Return to More Current References

Older References


    • Network-based analysis of omics with multi-objective optimization.
    • Mosca E, Milanesi L.
    • Mol Biosyst. 2013 Dec 29;9(12):2971-80. doi: 10.1039/c3mb70327d. Epub 2013 Oct 14.
    • Loss of heterozygosity at 13q13 and 14q32 predicts BRCA2 inactivation in luminal breast carcinomas.
    • Pécuchet N, Popova T, Manié E, Lucchesi C, Battistella A, Vincent-Salomon A, Caux-Moncoutier V, Bollet M, Sigal-Zafrani B, Sastre-Garau X, Stoppa-Lyonnet D, Stern MH.
    • Int J Cancer. 2013 Dec 15;133(12):2834-2842. doi: 10.1002/ijc.28315. Epub 2013 Jul 10.
    • Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models.
    • Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, Chen JY, Ohman AW, Stepule CD, Kwak S, Karst AM, Hirsch MS, Setlur SR, Crum CP, Dinulescu DM, Drapkin R.
    • Cancer Cell. 2013 Dec 9;24(6):751-65. doi: 10.1016/j.ccr.2013.10.013.

    Research news:

    Ovarian cancer: A better mimic.

    • Tackling the diversity of triple-negative breast cancer.
    • Turner NC, Reis-Filho JS.
    • Clin Cancer Res. 2013 Dec 1;19(23):6380-8. doi: 10.1158/1078-0432.CCR-13-0915.
    • Clinical implications of using molecular diagnostics for ovarian cancers.
    • Kohn EC, Romano S, Lee JM.
    • Ann Oncol. 2013 Dec;24 Suppl 10:x22-26. doi: 10.1093/annonc/mdt464.
    • Explaining variance in the cumulus mammographic measures that predict breast cancer risk: a twins and sisters study.
    • Nguyen TL, Schmidt DF, Makalic E, Dite GS, Stone J, Apicella C, Bui M, Macinnis RJ, Odefrey F, Cawson JN, Treloar SA, Southey MC, Giles GG, Hopper JL.
    • Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2395-403. doi: 10.1158/1055-9965.EPI-13-0481. Epub 2013 Oct 15.
    • Through the glass darkly: intraepithelial neoplasia, top-down differentiation, and the road to ovarian cancer.
    • Crum CP, Herfs M, Ning G, Bijron JG, Howitt BE, Jimenez CA, Hanamornroongruang S, McKeon FD, Xian W.
    • J Pathol. 2013 Dec;231(4):402-12. doi: 10.1002/path.4263.
    • MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency.
    • Ren J, Jin F, Yu Z, Zhao L, Wang L, Bai X, Zhao H, Yao W, Mi X, Wang E, Olopade OI, Wei M.
    • Tumour Biol. 2013 Dec;34(6):3945-58. doi: 10.1007/s13277-013-0983-9. Epub 2013 Jul 17.
    • MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours.
    • Tanic M, Andrés E, M Rodriguez-Pinilla S, Marquez-Rodas I, Cebollero-Presmanes M, Fernandez V, Osorio A, Benítez J, Martinez-Delgado B.
    • Br J Cancer. 2013 Nov 12;109(10):2724-34. doi: 10.1038/bjc.2013.612. Epub 2013 Oct 8.
    • Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
    • Birkbak NJ, Kochupurakkal B, Izarzugaza JM, Eklund AC, Li Y, Liu J, Szallasi Z, Matulonis UA, Richardson AL, Iglehart JD, Wang ZC.
    • PLoS One. 2013 Nov 12;8(11):e80023. doi: 10.1371/journal.pone.0080023. eCollection 2013.
    • Women with familial risk for breast cancer have an increased frequency of aldehyde dehydrogenase expressing cells in breast ductules.
    • Isfoss BL, Holmqvist B, Jernström H, Alm P, Olsson H.
    • BMC Clin Pathol. 2013 Nov 4;13(1):28. doi: 10.1186/1472-6890-13-28.
    • The role of the fallopian tube in the origin of ovarian cancer.
    • Erickson BK, Conner MG, Landen CN Jr.
    • Am J Obstet Gynecol. 2013 Nov;209(5):409-14. doi: 10.1016/j.ajog.2013.04.019. Epub 2013 Apr 10.

    Letter, Comment:

    Risk-reducing salpingectomy as a new and safe strategy to prevent ovarian cancer.

    Letter, Reply:

    Reply: To PMID 23583217.

    • Biology of hereditary breast and ovarian cancers.
    • Tommasi S.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii7. doi: 10.1093/annonc/mdt309.
    • Breast cancer risk in BRCA1 mutation carriers: insight from mouse models.
    • Barcellos-Hoff MH, Kleinberg DL.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii8-viii12. doi: 10.1093/annonc/mdt305.
    • Coming into focus: the nonovarian origins of ovarian cancer.
    • Dubeau L, Drapkin R.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii28-viii35. doi: 10.1093/annonc/mdt308.
    • Male breast cancer: genetics, epigenetics, and ethical aspects.
    • Rizzolo P, Silvestri V, Tommasi S, Pinto R, Danza K, Falchetti M, Gulino M, Frati P, Ottini L.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii75-viii82. doi: 10.1093/annonc/mdt316.
    • Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue.
    • Vilasco M, Communal L, Hugon-Rodin J, Penault-Llorca F, Mourra N, Wu Z, Forgez P, Gompel A; BRACAPS.
    • Breast Cancer Res Treat. 2013 Nov;142(2):283-96. doi: 10.1007/s10549-013-2722-8. Epub 2013 Oct 29.
    • MicroRNA signatures in hereditary breast cancer.
    • Murria Estal R, Palanca Suela S, de Juan Jiménez I, Egoavil Rojas C, García-Casado Z, Juan Fita MJ, Sánchez Heras AB, Segura Huerta A, Chirivella González I, Sánchez-Izquierdo D, Llop García M, Barragán González E, Bolufer Gilabert P.
    • Breast Cancer Res Treat. 2013 Nov;142(1):19-30. doi: 10.1007/s10549-013-2723-7. Epub 2013 Oct 16.
    • Increased Proliferative Background in Healthy Women with BRCA1/2 Haploinsufficiency Is Associated with High Risk for Breast Cancer.
    • Nisman B, Kadouri L, Allweis T, Maly B, Hamburger T, Gronowitz S, Peretz T.
    • Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2110-5. doi: 10.1158/1055-9965.EPI-13-0193. Epub 2013 Aug 21.
    • BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers.
    • Buckley NE, Nic An Tsaoir CB, Blayney JK, Oram LC, Crawford NT, D'Costa ZC, Quinn JE, Kennedy RD, Harkin DP, Mullan PB.
    • Nucleic Acids Res. 2013 Oct 1;41(18):8601-14. doi: 10.1093/nar/gkt626. Epub 2013 Jul 17.
    • The expression of BRCA1, P53, KAI1, and Nm23 in ovaries of BRCA1 mutation carriers after prophylactic adnexectomy.
    • Markowska J, Bar J, Mądry R, Słomska I, Mardas M, Grabowski JP.
    • Arch Gynecol Obstet. 2013 Oct;288(4):839-44. doi: 10.1007/s00404-013-2825-9. Epub 2013 Apr 4.
    • Pyrimidine base damage is increased in women with BRCA mutations.
    • Budzinski EE, Patrzyc HB, Dawidzik JB, Freund HG, Frederick P, Godoy HE, Voian NC, Odunsi K, Box HC.
    • Cancer Lett. 2013 Sep 28;338(2):267-70. doi: 10.1016/j.canlet.2013.04.001. Epub 2013 Apr 11.
    • Short telomeres are frequent in hereditary breast tumors and are associated with high tumor grade.
    • Martinez-Delgado B, Gallardo M, Tanic M, Yanowsky K, Inglada-Perez L, Barroso A, Rodriguez-Pinilla M, Cañamero M, Blasco MA, Benitez J.
    • Breast Cancer Res Treat. 2013 Sep;141(2):231-42. doi: 10.1007/s10549-013-2696-6. Epub 2013 Sep 15.
    • Copy neutral loss of heterozygosity is more frequent in older ovarian cancer patients.
    • Pedersen BS, Konstantinopoulos PA, Spillman MA, De S.
    • Genes Chromosomes Cancer. 2013 Sep;52(9):794-801. doi: 10.1002/gcc.22075. Epub 2013 May 28.
    • Cytogenetic finding of breast cancer cases and in their first-degree relatives.
    • Celik DA, Koşar PA, Ozçelik N, Eroğlu E.
    • J Breast Cancer. 2013 Sep;16(3):285-90. doi: 10.4048/jbc.2013.16.3.285. Epub 2013 Sep 30.
    • Association between BRCA Mutation Status, Pathological Findings, and Magnetic Resonance Imaging Features in Patients with Breast Cancer at Risk for the Mutation.
    • Noh JM, Han BK, Choi DH, Rhee SJ, Cho EY, Huh SJ, Park W, Park H, Nam SJ, Lee JE, Kil WH.
    • J Breast Cancer. 2013 Sep;16(3):308-14. doi: 10.4048/jbc.2013.16.3.308. Epub 2013 Sep 30.
    • Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
    • Yi YW, Kang HJ, Kim HJ, Hwang JS, Wang A, Bae
    • Mol Carcinog. 2013 Sep;52(9):667-75. doi: 10.1002/mc.21905. Epub 2012 Apr 4.
    • BRCA1 and p53 regulate critical prostate cancer pathways.
    • De Luca P, Moiola CP, Zalazar F, Gardner K, Vazquez ES, De Siervi A.
    • Prostate Cancer Prostatic Dis. 2013 Sep;16(3):233-8. doi: 10.1038/pcan.2013.12. Epub 2013 May 14.
    • Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis.
    • Bijron JG, Seldenrijk CA, Zweemer RP, Lange JG, Verheijen RH, van Diest PJ.
    • Am J Surg Pathol. 2013 Aug;37(8):1123-30. doi: 10.1097/PAS.0b013e318282da7f.
    • Case report

    Letter, Comment:

    Fallopian tube intraluminal tumor spread.

    Letter, Comment:

    Serous carcinogenesis: a classic causality dilemma or which came first... ?

    • Are bilateral breast cancers different from breast cancers coexisting with ovarian cancer? An immunohistochemical analysis aimed at intrinsic tumor phenotype.
    • Senkus E, Szade J, Pieczyńska B, Żaczek A, Brożek I, Radecka B, Kowalczyk A, Wełnicka-Jaśkiewicz M, Jassem J.
    • Breast. 2013 Aug;22(4):425-30. doi: 10.1016/j.breast.2013.04.005. Epub 2013 May 1.
    • Autophagy Opposes p53-Mediated Tumor Barrier to Facilitate Tumorigenesis in a Model of PALB2-Associated Hereditary Breast Cancer.
    • Huo Y, Cai H, Teplova I, Bowman-Colin C, Chen G, Price S, Barnard N, Ganesan S, Karantza V, White E, Xia B.
    • Cancer Discov. 2013 Aug;3(8):894-907. doi: 10.1158/2159-8290.CD-13-0011. Epub 2013 May 6.
    • Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer.
    • Danza K, Pilato B, Lacalamita R, Addati T, Giotta F, Bruno A, Paradiso A, Tommasi S.
    • Eur J Hum Genet. 2013 Aug;21(8):824-30. doi: 10.1038/ejhg.2012.273. Epub 2012 Dec 12.
    • The complex genetic landscape of familial breast cancer.
    • Melchor L, Benítez J.
    • Hum Genet. 2013 Aug;132(8):845-63. doi: 10.1007/s00439-013-1299-y. Epub 2013 Apr 5.
    • Review
    • Tuberin and p27 expression in breast cancer patients with or without BRCA germline mutations.
    • Dressler AC, Hudelist G, Fink-Retter A, Gschwantler-Kaulich D, Pfeiler G, Rosner M, Hengstschläger M, Singer CF.
    • J Cancer Res Clin Oncol. 2013 Aug;139(8):1349-55. doi: 10.1007/s00432-013-1443-z. Epub 2013 May 21.
    • Localization of BRCA1 protein in breast cancer tissue and cell lines with mutations.
    • Tulchin N, Ornstein L, Dikman S, Strauchen J, Jaffer S, Nagi C, Bleiweiss I, Kornreich R, Edelmann L, Brown K, Bodian C, Nair VD, Chambon M, Woods NT, Monteiro AN.
    • Cancer Cell Int. 2013 Jul 15;13(1):70. doi: 10.1186/1475-2867-13-70.
    • Tumour morphology predicts PALB2 germline mutation status.
    • Teo ZL, Provenzano E, Dite GS, Park DJ, Apicella C, Sawyer SD, James PA, Mitchell G, Trainer AH, Lindeman GJ, Shackleton K, Cicciarelli L; kConFab, Buys SS, Andrulis IL, Mulligan AM, Glendon G, John EM, Terry MB, Daly M, Odefrey FA, Nguyen-Dumont T, Giles GG, Dowty JG, Winship I, Goldgar DE, Hopper JL, Southey MC.
    • Br J Cancer. 2013 Jul 9;109(1):154-63. doi: 10.1038/bjc.2013.295. Epub 2013 Jun 20.
    • Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.
    • George J, Alsop K, Etemadmoghadam D, Hondow H, Mikeska T, Dobrovic A, deFazio A; Australian Ovarian Cancer Study Group, Smyth GK, Levine DA, Mitchell G, Bowtell DD.
    • Clin Cancer Res. 2013 Jul 1;19(13):3474-84. doi: 10.1158/1078-0432.CCR-13-0066. Epub 2013 Apr 30.

    Research news:

    Genomic signatures of BRCA1 but not BRCA2 associated high-grade serous carcinoma resemble basal-like breast cancer.

    • Tumour diploidy and survival in breast cancer patients with BRCA2 mutations.
    • Tryggvadottir L, Olafsdottir EJ, Olafsdottir GH, Sigurdsson H, Johannsson OT, Bjorgvinsson E, Alexiusdottir K, Stefansson OA, Agnarsson BA, Narod SA, Eyfjord JE, Jonasson JG.
    • Breast Cancer Res Treat. 2013 Jul;140(2):375-84. doi: 10.1007/s10549-013-2637-4. Epub 2013 Jul 16.
    • Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
    • Bane A, Viloria-Petit A, Pinnaduwage D, Mulligan AM, O'Malley FP, Andrulis IL.
    • Breast Cancer Res Treat. 2013 Jul;140(1):195-205. doi: 10.1007/s10549-013-2591-1. Epub 2013 Jun 28.
    • Relationship between family history of breast cancer and clinicopathological features in moroccan patients.
    • Tazzite A, Jouhadi H, Saiss K, Benider A, Nadifi S.
    • Ethiop J Health Sci. 2013 Jul;23(2):150-7.
    • Ovarian surface epithelium as a source of ovarian cancers: Unwarranted speculation or evidence-based hypothesis?
    • Auersperg N.
    • Gynecol Oncol. 2013 Jul;130(1):246-51. doi: 10.1016/j.ygyno.2013.03.021. Epub 2013 Apr 2.
    • Review
    • Risk factors for ovarian cancers with and without microsatellite instability.
    • Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, Zhang S, Ping S, Narod SA, Schildkraut J.
    • Int J Gynecol Cancer. 2013 Jul;23(6):1010-5. doi: 10.1097/IGC.0b013e31829a5527.

    Retraction:

    Retraction.

    • BRCA1-Dependent Translational Regulation in Breast Cancer Cells.
    • Dacheux E, Vincent A, Nazaret N, Combet C, Wierinckx A, Mazoyer S, Diaz JJ, Lachuer J, Venezia ND.
    • PLoS One. 2013 Jun 21;8(6):e67313. Print 2013.
    • Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions.
    • Chene G, Tchirkov A, Pierre-Eymard E, Dauplat J, Raoelfils I, Cayre A, Watkin E, Vago P, Penault-Llorca F.
    • Clin Cancer Res. 2013 Jun 1;19(11):2873-82. doi: 10.1158/1078-0432.CCR-12-3947. Epub 2013 Apr 15.

    Letter, Comment:

    Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions--letter.

    Letter, Reply:

    Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions--response.

    • Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer.
    • Alshareeda AT, Negm OH, Albarakati N, Green AR, Nolan C, Sultana R, Madhusudan S, Benhasouna A, Tighe P, Ellis IO, Rakha EA.
    • Breast Cancer Res Treat. 2013 Jun;139(2):301-10. doi: 10.1007/s10549-013-2542-x. Epub 2013 Apr 28.
    • Platform comparisons for identification of breast cancers with a BRCA-like copy number profile.
    • Schouten PC, van Dyk E, Braaf LM, Mulder L, Lips EH, de Ronde JJ, Holtman L, Wesseling J, Hauptmann M, Wessels LF, Linn SC, Nederlof PM.
    • Breast Cancer Res Treat. 2013 Jun;139(2):317-27. doi: 10.1007/s10549-013-2558-2. Epub 2013 May 14.
    • Different methylation and microRNA expression pattern in male and female familial breast cancer.
    • Pinto R, Pilato B, Ottini L, Lambo R, Simone G, Paradiso A, Tommasi S.
    • J Cell Physiol. 2013 Jun;228(6):1264-9. doi: 10.1002/jcp.24281.
    • Silencing of tumor suppressor genes RASSF1A, SLIT2, and WIF1 by promoter hypermethylation in hereditary breast cancer.
    • Alvarez C, Tapia T, Cornejo V, Fernandez W, Muñoz A, Camus M, Alvarez M, Devoto L, Carvallo P.
    • Mol Carcinog. 2013 Jun;52(6):475-87. doi: 10.1002/mc.21881. Epub 2012 Feb 7.
    • Prediction of BRCA1 germ-line mutation status in patients with breast cancer using histoprognosis grade, MS110, Lys27H3, vimentin, and KI67.
    • Hassanein M, Huiart L, Bourdon V, Rabayrol L, Geneix J, Nogues C, Peyrat JP, Gesta P, Meynard P, Dreyfus H, Petrot D, Lidereau R, Noguchi T, Eisinger F, Extra JM, Viens P, Jacquemier J, Sobol H.
    • Pathobiology. [2013 Jun;]80(5):219-27. doi: 10.1159/000339432. Epub 2013 Apr 23.
    • BRCA1 mutations and luminal-basal transformation.
    • Ng T, Irshad S, Stebbing J.
    • Oncogene. 2013 May 30;32(22):2712-4. doi: 10.1038/onc.2012.379. Epub 2012 Aug 27.
    • Comment

    Germline mutation of Brca1 alters the fate of mammary luminal cells and causes luminal-to-basal mammary tumor transformation.

    • Germline mutation of Brca1 alters the fate of mammary luminal cells and causes luminal-to-basal mammary tumor transformation.
    • Bai F, Smith MD, Chan HL, Pei XH.
    • Oncogene. 2013 May 30;32(22):2715-25. doi: 10.1038/onc.2012.293. Epub 2012 Jul 9.

    Comment:

    BRCA1 mutations and luminal-basal transformation.

    • Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling.
    • Larsen MJ, Kruse TA, Tan Q, Lænkholm AV, Bak M, Lykkesfeldt AE, Sørensen KP, Hansen TV, Ejlertsen B, Gerdes AM, Thomassen M.
    • PLoS One. 2013 May 21;8(5):e64268. doi: 10.1371/journal.pone.0064268. Print 2013.
    • Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer.
    • Bowman-Colin C, Xia B, Bunting S, Klijn C, Drost R, Bouwman P, Fineman L, Chen X, Culhane AC, Cai H, Rodig SJ, Bronson RT, Jonkers J, Nussenzweig A, Kanellopoulou C, Livingston DM.
    • Proc Natl Acad Sci U S A. 2013 May 21;110(21):8632-7. doi: 10.1073/pnas.1305362110. Epub 2013 May 8.
    • Male breast cancer according to tumor subtype and race : A population-based study.
    • Chavez-Macgregor M, Clarke CA, Lichtensztajn D, Hortobagyi GN, Giordano SH.
    • Cancer. 2013 May 1;119(9):1611-7. doi: 10.1002/cncr.27905. Epub 2013 Jan 22.
    • TNRC9 downregulates BRCA1 expression and promotes breast cancer aggressiveness.
    • Shan J, Dsouza SP, Bakhru S, Al-Azwani EK, Ascierto ML, Sastry KS, Bedri S, Kizhakayil D, Aigha II, Malek J, Al-Bozom I, Gehani S, Furtado S, Mathiowitz E, Wang E, Marincola FM, Chouchane L.
    • Cancer Res. 2013 May 1;73(9):2840-9. doi: 10.1158/0008-5472.CAN-12-4313. Epub 2013 Feb 27.
    • Heterozygous mutations in the PALB2 hereditary breast cancer predisposition gene impact on the three-dimensional nuclear organization of patient-derived cell lines.
    • Wark L, Novak D, Sabbaghian N, Amrein L, Jangamreddy JR, Cheang M, Pouchet C, Aloyz R, Foulkes WD, Mai S, Tischkowitz M.
    • Genes Chromosomes Cancer. 2013 May;52(5):480-94. doi: 10.1002/gcc.22045. Epub 2013 Jan 23.
    • SULT1A1 gene deletion in BRCA2-associated male breast cancer: a link between genes and environmental exposures?
    • Palli D, Rizzolo P, Zanna I, Silvestri V, Saieva C, Falchetti M, Navazio AS, Graziano V, Masala G, Bianchi S, Russo A, Tommasi S, Ottini L.
    • J Cell Mol Med. 2013 May;17(5):605-7. doi: 10.1111/jcmm.12043.
    • DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas.
    • Kamieniak MM, Muñoz-Repeto I, Rico D, Osorio A, Urioste M, García-Donas J, Hernando S, Robles-Díaz L, Ramón Y Cajal T, Cazorla A, Sáez R, García-Bueno JM, Domingo S, Borrego S, Palacios J, van de Wiel MA, Ylstra B, Benítez J, García MJ.
    • Br J Cancer. 2013 Apr 30;108(8):1732-42. doi: 10.1038/bjc.2013.141. Epub 2013 Apr 4.
    • No evidence for PALB2 methylation in high-grade serous ovarian cancer.
    • Mikeska T, Alsop K; Australian Ovarian Cancer Study Group, Mitchell G, Bowtell DD, Dobrovic A.
    • J Ovarian Res. 2013 Apr 12;6(1):26. doi: 10.1186/1757-2215-6-26.
    • Salpingectomy: Can removing the fallopian tubes lower ovarian cancer risk?
    • Ilana Cass, Doug Levine
    • FORCE. Be Empowered Webinars. 2013 Apr 11.
    • Lipid metabolism genes in contralateral unaffected breast and estrogen receptor status of breast cancer.
    • Wang J, Scholtens D, Holko M, Ivancic D, Lee O, Hu H, Chatterton RT Jr, Sullivan ME, Hansen N, Bethke K, Zalles CM, Khan SA.
    • Cancer Prev Res (Phila). 2013 Apr;6(4):321-30. doi: 10.1158/1940-6207.CAPR-12-0304. Epub 2013 Mar 19.

    Press: Breast cancer gene test could allow preventive treatment. (The Telegraph)

    • Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers.
    • Reitsma W, Mourits MJ, de Bock GH, Hollema H.
    • Mod Pathol. 2013 Apr;26(4):572-8. doi: 10.1038/modpathol.2012.169. Epub 2012 Oct 19.
    • Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient.
    • Zhang J, Shi Y, Lalonde E, Li L, Cavallone L, Ferenczy A, Gotlieb WH, Foulkes WD, Majewski J.
    • BMC Cancer. 2013 Mar 22;13:146. doi: 10.1186/1471-2407-13-146.
    • Male breast cancer, age and sex chromosome aneuploidy.
    • Jacobs PA, Maloney V, Cooke R, Crolla JA, Ashworth A, Swerdlow AJ.
    • Br J Cancer. 2013 Mar 5;108(4):959-63. doi: 10.1038/bjc.2012.577. Epub 2013 Jan 8.
    • Surgical implications of the potential new tubal pathway for ovarian carcinogenesis.
    • Chene G, Rahimi K, Mes-Masson AM, Provencher D.
    • J Minim Invasive Gynecol. 2013 Mar-Apr;20(2):153-9. doi: 10.1016/j.jmig.2012.11.010. Epub 2013 Jan 16.
    • Review
    • Absence of loss of heterozygosity of BRCA1 in a renal tumor from a BRCA1 germline mutation carrier.
    • Alanee S, Shah S, Murali R, Rau-Murthy R, Schrader KA, Offit K.
    • Fam Cancer. 2013 Mar;12(1):125-7. doi: 10.1007/s10689-012-9572-0.
    • Case report, Letter

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: Should I test for Cowden?

    • 53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.
    • Pennington KP, Wickramanayake A, Norquist BM, Pennil CC, Garcia RL, Agnew KJ, Taniguchi T, Welcsh P, Swisher EM.
    • Gynecol Oncol. 2013 Mar;128(3):493-9. doi: 10.1016/j.ygyno.2012.12.007. Epub 2012 Dec 12.
    • Re: "A low-grade ovarian carcinoma case with coincident LOH of PTCH1 and BRCA1, and a mutation in BRCA1," Int J Gyn Pathol 2012 May;31: 264-271.
    • Köbel M, Ghatage P.
    • Int J Gynecol Pathol. 2013 Mar;32(2):176. doi: 10.1097/PGP.0b013e31826b4ea1.
    • Comment, Letter

    Case report:

    A low-grade ovarian carcinoma case with coincident LOH of PTCH1 and BRCA1, and a mutation in BRCA1.

    Letter, Reply:

    In reply.

    • HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.
    • van der Groep P, van Diest PJ, Smolders YH, Ausems MG, van der Luijt RB, Menko FH, Bart J, de Vries EG, van der Wall E.
    • PLoS One. 2013;8(2):e56055. doi: 10.1371/journal.pone.0056055. Epub 2013 Feb 8.
    • Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer.
    • Hsu NC, Huang YF, Yokoyama KK, Chu PY, Chen FM, Hou MF.
    • PLoS One. 2013;8(2):e56256. doi: 10.1371/journal.pone.0056256. Epub 2013 Feb 6.
    • BRCA2 Dysfunction Promotes Malignant Transformation of Pancreatic Intraepithelial Neoplasia.
    • Wang Q, Liu H, Liu T, Shu S, Jiang H, Cheng S, Yuan Y, Yang W, Wang L.
    • Anticancer Agents Med Chem. 2013 Feb 1;13(2):261-9.
    • Determination of Molecular Markers for BRCA1 and BRCA2 Heterozygosity Using Gene Expression Profiling.
    • Salmon AY, Salmon-Divon M, Zahavi T, Barash Y, Levy-Drummer RS, Jacob-Hirsch J, Peretz T.
    • Cancer Prev Res (Phila). 2013 Feb;6(2):82-90. doi: 10.1158/1940-6207.CAPR-12-0105. Epub 2013 Jan 22.

    Research News:

    New test predicts BRCA1 and BRCA2 mutations.

    Press: The Future of BRCA1/BRCA2 Testing. (OncLive)

    • Genetics of Susceptibility to Sporadic Ovarian Cancer.
    • Katabathina VS, Prasad SR.
    • eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net. doi: 10.1002/9780470015902.a0023853. 2013 Feb.
    • Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression.
    • Wang YQ, Yan Q, Zhang JR, Li SD, Yang YX, Wan XP.
    • J Obstet Gynaecol Res. 2013 Feb;39(2):549-54. doi: 10.1111/j.1447-0756.2012.01979.x. Epub 2012 Sep 25.
    • Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry.
    • Mulligan AM, Raitman I, Feeley L, Pinnaduwage D, Nguyen LT, O'Malley FP, Ohashi PS, Andrulis IL.
    • Clin Cancer Res. 2013 Jan 15;19(2):336-46. doi: 10.1158/1078-0432.CCR-11-3314. Epub 2012 Dec 4.
    • VEGF, HIF-1α expression and MVD as an angiogenic network in familial breast cancer.
    • http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0053070Saponaro C, Malfettone A, Ranieri G, Danza K, Simone G, Paradiso A, Mangia A.
    • PLoS One. 2013;8(1):e53070. doi: 10.1371/journal.pone.0053070. Epub 2013 Jan 11.
    • BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
    • Garg K, Levine DA, Olvera N, Dao F, Bisogna M, Secord AA, Berchuck A, Cerami E, Schultz N, Soslow RA.
    • Am J Surg Pathol. 2013 Jan;37(1):138-46. doi: 10.1097/PAS.0b013e31826cabbd.
    • Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.
    • Reitsma W, de Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJ.
    • Eur J Cancer. 2013 Jan;49(1):132-41. doi: 10.1016/j.ejca.2012.07.021. Epub 2012 Aug 21.
    • Phenotypic characterization of hereditary epithelial ovarian cancer based on a tissue microarray study.
    • Muñoz-Repeto I, García MJ, Kamieniak M, Ramón Y Cajal T, Domingo S, Cazorla A, García Donas J, Hernando Polo S, García Sagredo JM, Hernández E, Lacambra C, Saez R, Robles L, Borrego S, Prat J, Palacios J, Benítez J.
    • Histol Histopathol. 2013 Jan;28(1):133-44.
    • HOX gene methylation status analysis in patients with hereditary breast cancer.
    • Pilato B, Pinto R, De Summa S, Lambo R, Paradiso A, Tommasi S.
    • J Hum Genet. 2013 Jan;58(1):51-3. doi: 10.1038/jhg.2012.118. Epub 2012 Oct 11.
    • PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer.
    • Deb S, Do H, Byrne D, Jene N; kConFab Investigators, Dobrovic A, Fox SB.
    • Breast Cancer Res. 2013;15(4):R69.
    • The ectopic expression of BRCA1 is associated with genesis, progression, and prognosis of breast cancer in young patients.
    • Zhang Q, Zhang Q, Cong H, Zhang X.
    • Diagn Pathol. 2012 Dec 31;7:181. doi: 10.1186/1746-1596-7-181.
    • Deletion of chromosomes 13q and 14q is a common feature of tumors with BRCA2 mutations.
    • Rouault A, Banneau G, Macgrogan G, Jones N, Elarouci N, Barouk-Simonet E, Venat L, Coupier I, Letouzé E, de Reyniès A, Bonnet F, Iggo R, Sévenet N, Longy M.
    • PLoS One. 2012;7(12):e52079. doi: 10.1371/journal.pone.0052079. Epub 2012 Dec 21.
    • Mitochondrial DNA mutation in serous ovarian cancer: implications for mitochondria-coded genes in chemoresistance.
    • Guerra F, Perrone AM, Kurelac I, Santini D, Ceccarelli C, Cricca M, Zamagni C, De Iaco P, Gasparre G.
    • J Clin Oncol. 2012 Dec 20;30(36):e373-8. doi: 10.1200/JCO.2012.43.5933. Epub 2012 Nov 13.
    • Ovarian cancer molecular pathology.
    • Longuespée R, Boyon C, Desmons A, Vinatier D, Leblanc E, Farré I, Wisztorski M, Ly K, D'Anjou F, Day R, Fournier I, Salzet M.
    • Cancer Metastasis Rev. 2012 Dec;31(3-4):713-32. doi: 10.1007/s10555-012-9383-7.
    • Review
    • IGF-1 and BRCA1 signalling pathways in familial cancer.
    • Werner H, Bruchim I.
    • Lancet Oncol. 2012 Dec;13(12):E537-44. doi: 10.1016/S1470-2045(12)70362-5.
    • Review
    • BRCA2 promoter hypermethylation in sporadic breast cancer.
    • Bosviel R, Durif J, Guo J, Mebrek M, Kwiatkowski F, Bignon YJ, Bernard-Gallon DJ.
    • OMICS. 2012 Dec;16(12):707-10. doi: 10.1089/omi.2012.0060.
    • Hereditary ovarian cancer and two-compartment tumor metabolism: Epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFκB activation in the tumor stroma.
    • Martinez-Outschoorn UE, Balliet RM, Lin Z, Whitaker-Menezes D, Howell A, Sotgia F, Lisanti MP.
    • Cell Cycle. 2012 Nov 15;11(22):4152-66. doi: 10.4161/cc.22226. Epub 2012 Oct 9.
    • Proliferation in the Normal FTE Is a Hallmark of the Follicular Phase, Not BRCA Mutation Status.
    • George SH, Milea A, Shaw PA.
    • Clin Cancer Res. 2012 Nov 15;18(22):6199-207. doi: 10.1158/1078-0432.CCR-12-2155. Epub 2012 Sep 11.
    • Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation.
    • Popova T, Manié E, Rieunier G, Caux-Moncoutier V, Tirapo C, Dubois T, Delattre O, Sigal-Zafrani B, Bollet M, Longy M, Houdayer C, Sastre-Garau X, Vincent-Salomon A, Stoppa-Lyonnet D, Stern MH.
    • Cancer Res. 2012 Nov 1;72(21):5454-62. doi: 10.1158/0008-5472.CAN-12-1470. Epub 2012 Aug 29.
    • Uncertainty in the utility of immunohistochemistry in mismatch repair protein expression in epithelial ovarian cancer.
    • Coppola D, Nicosia SV, Doty A, Sellers TA, Lee JH, Fulp J, Thompson Z, Galeb S, McLaughlin J, Narod SA, Schildkraut J, Pal T.
    • Anticancer Res. 2012 Nov;32(11):4963-9.
    • E2F3b over-expression in ovarian carcinomas and in BRCA1 haploinsufficient fallopian tube epithelium.
    • Smith NL, Welcsh P, Press JZ, Agnew KJ, Garcia R, Swisher EM.
    • Genes Chromosomes Cancer. 2012 Nov;51(11):1054-62. doi: 10.1002/gcc.21990. Epub 2012 Aug 9.
    • Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing.
    • de la Cruz J, Andre F, Harrell RK, Bassett RL Jr, Arun B, Mathieu MC, Delaloge S, Gilcrease MZ.
    • Hum Pathol. 2012 Nov;43(11):1932-9. doi: 10.1016/j.humpath.2012.02.002. Epub 2012 May 14.
    • Prevalence of loss of expression of DNA mismatch repair proteins in primary epithelial ovarian tumors.
    • Lu FI, Gilks CB, Mulligan AM, Ryan P, Allo G, Sy K, Shaw PA, Pollett A, Clarke BA.
    • Int J Gynecol Pathol. 2012 Nov;31(6):524-31. doi: 10.1097/PGP.0b013e31824fe2aa.
    • Comprehensive molecular portraits of human breast tumours.
    • Cancer Genome Atlas Network.
    • Nature. 2012 Oct 4;490(7418):61-70. doi: 10.1038/nature11412. Epub 2012 Sep 23.

    Press: Study Divides Breast Cancer Into Four Distinct Types (New York Times)

    • Pathologic features and immunophenotype of estrogen receptor-positive breast cancers in BRCA1 mutation carriers.
    • Kaplan JS, Schnitt SJ, Collins LC, Wang Y, Garber JE, Montgomery K, West RB, Krag K, Fetten K, Lincoln A, Tung NM.
    • Am J Surg Pathol. 2012 Oct;36(10):1483-8. doi: 10.1097/PAS.0b013e31825789ed.
    • Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls.
    • Mingels MJ, Roelofsen T, van der Laak JA, de Hullu JA, van Ham MA, Massuger LF, Bulten J, Bol M.
    • Gynecol Oncol. 2012 Oct;127(1):88-93. doi: 10.1016/j.ygyno.2012.06.015. Epub 2012 Jun 16.
    • Peritoneal cytology in risk-reducing salpingo-oophorectomy: Implications for cancer outcomes.
    • Chen L, McAlhaney S, Fehniger J, Powell C, Crawford B, Mak J, Rabban J.
    • Gynecol Oncol. 2012 Oct;127(1 Suppl):S17. doi: 10.1016/j.ygyno.2012.07.047.
    • Conference abstract
    • Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.
    • Oonk AM, van Rijn C, Smits MM, Mulder L, Laddach N, Savola SP, Wesseling J, Rodenhuis S, Imholz AL, Lips EH.
    • Ann Oncol. 2012 Sep;23(9):2301-5. doi: 10.1093/annonc/mdr621. Epub 2012 Feb 21.

    Free text: Clinical Correlates of 'BRCAness' in Triple-Negative Breast Cancer of Patients Receiving Adjuvant Chemotherapy. (Medscape)

    • BRCA1 immunohistochemistry assay: can it play a role in assessing sporadic early-onset breast cancer?
    • Roehe AV, Boff AL, Damin A.
    • Breast J. 2012 Sep;18(5):500-1. doi: 10.1111/j.1524-4741.2012.01292.x. Epub 2012 Aug 16.
    • Letter
    • Methylation profiles of the BRCA1 promoter in hereditary and sporadic breast cancer among Han Chinese.
    • Pang D, Zhao Y, Xue W, Shan M, Chen Y, Zhang Y, Zhang G, Liu F, Li D, Yang Y.
    • Med Oncol. 2012 Sep;29(3):1561-8. doi: 10.1007/s12032-011-0100-0. Epub 2011 Nov 11.
    • BRCA1--conductor of the breast stem cell orchestra: the role of BRCA1 in mammary gland development and identification of cell of origin of BRCA1 mutant breast cancer.
    • Buckley NE, Mullan PB.
    • Stem Cell Rev. 2012 Sep;8(3):982-93. doi: 10.1007/s12015-012-9354-y.
    • Review
    • BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression.
    • Bal A, Verma S, Joshi K, Singla A, Thakur R, Arora S, Singh G.
    • Virchows Arch. 2012 Sep;461(3):305-12. doi: 10.1007/s00428-012-1286-z. Epub 2012 Jul 21.
    • Tumour morphology of early-onset breast cancers predicts breast cancer risk for first-degree relatives: the Australian Breast Cancer Family Registry.
    • Dite GS, Makalic E, Schmidt DF, Giles GG, Hopper JL, Southey MC.
    • Breast Cancer Res. 2012 Aug 28;14(4):R122. doi: 10.1186/bcr3248.
    • The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer.
    • Jönsson G, Staaf J, Vallon-Christersson J, Ringnér M, Gruvberger-Saal SK, Saal LH, Holm K, Hegardt C, Arason A, Fagerholm R, Persson C, Grabau D, Johnsson E, Lövgren K, Magnusson L, Heikkilä P, Agnarsson BA, Johannsson OT, Malmström P, Fernö M, Olsson H, Loman N, Nevanlinna H, Barkardottir RB, Borg Å.
    • Cancer Res. 2012 Aug 15;72(16):4028-36. Epub 2012 Jun 15.
    • Prolonged postovulatory proinflammatory signaling in the fallopian tube epithelium may be mediated through a BRCA1/DAB2 axis.
    • Tone AA, Virtanen C, Shaw P, Brown TJ.
    • Clin Cancer Res. 2012 Aug 15;18(16):4334-44. doi: 10.1158/1078-0432.CCR-12-0199. Epub 2012 Jul 2.
    • Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype.
    • Fujiwara M, McGuire VA, Felberg A, Sieh W, Whittemore AS, Longacre TA.
    • Am J Surg Pathol. 2012 Aug;36(8):1170-7. doi: 10.1097/PAS.0b013e31825d9b8d.
    • BRCA1 exon 11 alternative splicing, multiple functions and the association with cancer.
    • Tammaro C, Raponi M, Wilson DI, Baralle D.
    • Biochem Soc Trans. 2012 Aug;40(4):768-72. doi: 10.1042/BST20120140.
    • Germline copy number variants are not associated with globally acquired copy number changes in familial breast tumours.
    • Walker LC, Krause L; kConFab Investigators, Spurdle AB, Waddell N.
    • Breast Cancer Res Treat. 2012 Aug;134(3):1005-11. Epub 2012 Mar 21.
    • Promoter hypermethylation in male breast cancer: analysis by multiplex ligation-dependent probe amplification.
    • Kornegoor R, Moelans CB, Verschuur-Maes AH, Hogenes MCh, de Bruin PC, Oudejans JJ, van Diest PJ.
    • Breast Cancer Res. 2012 Jul 5;14(4):R101. doi: 10.1186/bcr3220.
    • Molecular insights on basal-like breast cancer.
    • Valentin MD, da Silva SD, Privat M, Alaoui-Jamali M, Bignon YJ.
    • Breast Cancer Res Treat. 2012 Jul;134(1):21-30. doi: 10.1007/s10549-011-1934-z. Epub 2012 Jan 11.
    • Review
    • Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients.
    • Fumagalli C, Pruneri G, Possanzini P, Manzotti M, Barile M, Feroce I, Colleoni M, Bonanni B, Maisonneuve P, Radice P, Viale G, Barberis M.
    • Breast Cancer Res Treat. 2012 Jul;134(1):131-7. doi: 10.1007/s10549-011-1945-9. Epub 2012 Jan 8.
    • What drives breast cancer heterogeneity: oncogenic events or cell of origin?
    • Ginestier C, Charafe-Jauffret E, Birnbaum D.
    • J Pathol. 2012 Jul;227(3):267-9. doi: 10.1002/path.4028. Epub 2012 May 8.

    A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers.

    • Expression of TopBP1 in hereditary breast cancer.
    • Forma E, Krzeslak A, Bernaciak M, Romanowicz-Makowska H, Brys M.
    • Mol Biol Rep. 2012 Jul;39(7):7795-804. doi: 10.1007/s11033-012-1622-z. Epub 2012 Apr 28.
    • Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer.
    • Warmoes M, Jaspers JE, Pham TV, Piersma SR, Oudgenoeg G, Massink MP, Waisfisz Q, Rottenberg S, Boven E, Jonkers J, Jimenez CR.
    • Mol Cell Proteomics. 2012 Jul;11(7):M111.013334. doi: 10.1074/mcp.M111.013334. Epub 2012 Feb 24.
    • Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene.
    • Tanic M, Yanowsky K, Rodriguez-Antona C, Andrés R, Márquez-Rodas I, Osorio A, Benitez J, Martinez-Delgado B.
    • PLoS One. 2012;7(6):e38847. doi: 10.1371/journal.pone.0038847. Epub 2012 Jun 11.
    • Role of BRCA1 in controlling mitotic arrest in ovarian cystadenoma cells.
    • Yu VM, Marion CM, Austria TM, Yeh J, Schönthal AH, Dubeau L.
    • Int J Cancer. 2012 Jun 1;130(11):2495-504. doi: 10.1002/ijc.26309. Epub 2011 Aug 29.
    • Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours.
    • Holm K, Staaf J, Jönsson G, Vallon-Christersson J, Gunnarsson H, Arason A, Magnusson L, Barkardottir RB, Hegardt C, Ringnér M, Borg A.
    • Breast Cancer Res Treat. 2012 Jun;133(2):583-94. doi: 10.1007/s10549-011-1817-3. Epub 2011 Oct 16.
    • Evolutionary pathways in BRCA1-associated breast tumors.
    • Martins FC, De S, Almendro V, Gönen M, Park SY, Blum JL, Herlihy W, Ethington G, Schnitt SJ, Tung N, Garber JE, Fetten K, Michor F, Polyak K.
    • Cancer Discov. 2012 Jun;2(6):503-11. doi: 10.1158/2159-8290.CD-11-0325. Epub 2012 Apr 10.

    Comment:

    Tracking evolution of BRCA1-associated breast cancer.

    • Can a simple blood test really predict breast cancer?
    • McCartney M.
    • BMJ. 2012 May 15;344:e3374. doi: 10.1136/bmj.e3374.
    • News
    • Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk.
    • Brennan K, Garcia-Closas M, Orr N, Fletcher O, Jones M, Ashworth A, Swerdlow A, Thorne H; KConFab Investigators, Riboli E, Vineis P, Dorronsoro M, Clavel-Chapelon F, Panico S, Onland-Moret NC, Trichopoulos D, Kaaks R, Khaw KT, Brown R, Flanagan JM.
    • Cancer Res. 2012 May 1;72(9):2304-13. Epub 2012 Feb 28.

    News: Epigenetic test could inform breast cancer risk prediction. (PHG Foundation)

    • Loss of heterozygosity at BRCA1 locus is significantly associated with aggressiveness and poor prognosis in breast cancer.
    • Okada S, Tokunaga E, Kitao H, Akiyoshi S, Yamashita N, Saeki H, Oki E, Morita M, Kakeji Y, Maehara Y.
    • Ann Surg Oncol. 2012 May;19(5):1499-507. doi: 10.1245/s10434-011-2166-5. Epub 2011 Dec 17.
    • Allelic transcripts dosage effect in morphologically normal ovarian cells from heterozygous carriers of a BRCA1/2 French Canadian founder mutation.
    • Abd-Rabbo D, Abaji C, Cardin GB, Filali-Mouhim A, Arous C, Portelance L, Escobar E, Cloutier S, Tonin PN, Provencher DM, Mes-Masson AM, Maugard CM.
    • Cancer Prev Res (Phila). 2012 May;5(5):765-77. doi: 10.1158/1940-6207.CAPR-11-0547. Epub 2012 Mar 8.
    • The role of the fallopian tube in ovarian cancer.
    • Tone AA, Salvador S, Finlayson SJ, Tinker AV, Kwon JS, Lee CH, Cohen T, Ehlen T, Lee M, Carey MS, Heywood M, Pike J, Hoskins PJ, Stuart GC, Swenerton KD, Huntsman DG, Gilks CB, Miller DM, McAlpine JN.
    • Clin Adv Hematol Oncol. 2012 May;10(5):296-306.
    • The power of DNA double-strand break (DSB) repair testing to predict breast cancer susceptibility.
    • Keimling M, Deniz M, Varga D, Stahl A, Schrezenmeier H, Kreienberg R, Hoffmann I, König J, Wiesmüller L.
    • FASEB J. 2012 May;26(5):2094-104. doi: 10.1096/fj.11-200790. Epub 2012 Jan 25.
    • BRCA, the oviduct, and the space and time continuum of pelvic serous carcinogenesis.
    • Crum CP, McKeon FD, Xian W.
    • Int J Gynecol Cancer. 2012 May;22 Suppl 1:S29-34. doi: 10.1097/IGC.0b013e31824d7269.
    • A low-grade ovarian carcinoma case with coincident LOH of PTCH1 and BRCA1, and a mutation in BRCA1.
    • Maurac I, Sabol M, Musani V, Car D, Ozretic P, Kalafatic D, Oreskovic S, Babic D, Levanat S.
    • Int J Gynecol Pathol. 2012 May;31(3):264-71. doi: 10.1097/PGP.0b013e31823b6f0f.
    • Case Report

    Comment, Letter:

    Re: "A low-grade ovarian carcinoma case with coincident LOH of PTCH1 and BRCA1, and a mutation in BRCA1," Int J Gyn Pathol 2012 May;31: 264-271.

    • Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers.
    • Custodio A, López-Farré AJ, Zamorano-León JJ, Mateos-Cáceres PJ, Macaya C, Caldés T, de la Hoya M, Olivera E, Puente J, Díaz-Rubio E, Pérez-Segura P.
    • J Cancer Res Clin Oncol. 2012 May;138(5):867-75. doi: 10.1007/s00432-012-1161-y. Epub 2012 Feb 7.
    • Shorter telomere length is associated with increased ovarian cancer risk in both familial and sporadic cases.
    • Martinez-Delgado B, Yanowsky K, Inglada-Perez L, de la Hoya M, Caldes T, Vega A, Blanco A, Martin T, Gonzalez-Sarmiento R, Blasco M, Robledo M, Urioste M, Song H, Pharoah P, Benitez J.
    • J Med Genet. 2012 May;49(5):341-4. Epub 2012 Apr 6.

    Free Full Text: Shorter Telomere Length Is Associated With Increased Ovarian Cancer Risk in Both Familial and Sporadic Cases. (Medscape Oncology)

    • BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
    • McAlpine JN, Porter H, Köbel M, Nelson BH, Prentice LM, Kalloger SE, Senz J, Milne K, Ding J, Shah SP, Huntsman DG, Gilks CB.
    • Mod Pathol. 2012 May;25(5):740-50. doi: 10.1038/modpathol.2011.211. Epub 2012 Jan 27.
    • Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers.
    • Yan M, Xu H, Waddell N, Shield-Artin K, Haviv I; kConFab authors, McKay MJ, Fox SB.
    • Breast Cancer Res. 2012 Apr 26;14(2):R69.
    • The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
    • Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S; METABRIC Group, Langerød A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Børresen-Dale AL, Brenton JD, Tavaré S, Caldas C, Aparicio S.
    • Nature. 2012 Apr 18;486(7403):346-52. doi: 10.1038/nature10983.

    Comment:

    Copy number aberrations define breast cancer subgroups.

    Comment:

    Who's driving anyway? Herculean efforts to identify the drivers of breast cancer.

    Comment:

    Genomics: the breast cancer landscape.

    Comment:

    The breast cancer genome and the complexity of different subgroups: what does it all mean?

    News: Genetic map leads to new thinking on breast cancer. (PHG Foundation)

    • Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
    • Joosse SA, Brandwijk KI, Devilee P, Wesseling J, Hogervorst FB, Verhoef S, Nederlof PM.
    • Breast Cancer Res Treat. 2012 Apr;132(2):379-89. doi: 10.1007/s10549-010-1016-7. Epub 2010 Jul 8.
    • Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression.
    • Alford SH, Toy K, Merajver SD, Kleer CG.
    • Breast Cancer Res Treat. 2012 Apr;132(2):429-37. doi: 10.1007/s10549-011-1591-2. Epub 2011 May 26.
    • Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes.
    • Nagel JH, Peeters JK, Smid M, Sieuwerts AM, Wasielewski M, de Weerd V, Trapman-Jansen AM, van den Ouweland A, Brüggenwirth H, van Ijcken WF, Klijn JG, van der Spek PJ, Foekens JA, Martens JW, Schutte M, Meijers-Heijboer H.
    • Breast Cancer Res Treat. 2012 Apr;132(2):439-48. doi: 10.1007/s10549-011-1588-x. Epub 2011 May 26.
    • Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.
    • Soslow RA, Han G, Park KJ, Garg K, Olvera N, Spriggs DR, Kauff ND, Levine DA.
    • Mod Pathol. 2012 Apr;25(4):625-36. doi: 10.1038/modpathol.2011.183. Epub 2011 Dec 23.
    • Promoter methylation status and expression of estrogen receptor alpha in familial breast cancer patients.
    • Wei J, Han B, Mao XY, Wei MJ, Yao F, Jin F.
    • Tumour Biol. 2012 Apr;33(2):413-20. doi: 10.1007/s13277-011-0234-x. Epub 2011 Sep 16.
    • APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer.
    • Brough R, Bajrami I, Vatcheva R, Natrajan R, Reis-Filho JS, Lord CJ, Ashworth A.
    • EMBO J. 2012 Mar 7;31(5):1160-76. doi: 10.1038/emboj.2011.490. Epub 2012 Jan 31.
    • High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations.
    • Rzepecka IK, Szafron L, Stys A, Bujko M, Plisiecka-Halasa J, Madry R, Osuch B, Markowska J, Bidzinski M, Kupryjanczyk J.
    • Cancer Genet. 2012 Mar;205(3):94-100. doi: 10.1016/j.cancergen.2011.12.005.
    • Impact of lifestyle factors on preneoplastic changes in prophylactic oophorectomies of BRCA mutation carriers.
    • Primas H, Kroiss R, Kalteis K, Rappaport C, Muhr D, Primas C, Kubista E, Horvat R, Oefner P, Singer C, Wagner And The Austrian Hereditary Breast And Ovarian Cancer Group T.
    • Eur J Cancer Prev. 2012 Mar;21(2):199-204. doi: 10.1097/CEJ.0b013e32834c9b22.
    • Clinical implications for BRCA gene mutation in breast cancer.
    • Xu J, Wang B, Zhang Y, Li R, Wang Y, Zhang S.
    • Mol Biol Rep. 2012 Mar;39(3):3097-102. doi: 10.1007/s11033-011-1073-y. Epub 2011 Jun 21.
    • BRCA1 haploinsufficiency: consequences for breast cancer.
    • Salmena L, Narod S.
    • Womens Health (Lond Engl). 2012 Mar;8(2):127-9. doi: 10.2217/whe.12.2.
    • Commentary

    Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.

    • c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer.
    • Regan JL, Kendrick H, Magnay FA, Vafaizadeh V, Groner B, Smalley MJ.
    • Oncogene. 2012 Feb 16;31(7):869-83. doi: 10.1038/onc.2011.289. Epub 2011 Jul 18.
    • Role of micronucleus test in predicting breast cancer susceptibility: a systematic review and meta-analysis.
    • Cardinale F, Bruzzi P, Bolognesi C.
    • Br J Cancer. 2012 Feb 14;106(4):780-90. doi: 10.1038/bjc.2011.567. Epub 2011 Dec 20.
    • Promoter hypermethylation patterns in fallopian tube epithelium of BRCA1 and BRCA2 germ line mutation carriers.
    • Bijron JG, van der Groep P, van Dorst EB, Seeber LM, Sie-Go DM, Verheijen RH, van Diest PJ.
    • Endocr Relat Cancer. 2012 Feb 13;19(1):69-81. doi: 10.1530/ERC-11-0338. Print 2012 Feb.

    Comment:

    Epigenetic modification and cancer: mark or stamp?

    • The breast cancer susceptibility gene BRCA2 is required for the maintenance of telomere homeostasis.
    • Min J, Choi ES, Hwang K, Kim J, Sampath S, Venkitaraman AR, Lee H.
    • J Biol Chem. 2012 Feb 10;287(7):5091-101. doi: 10.1074/jbc.M111.278994. Epub 2011 Dec 20.
    • Functional differences among BRCA1 missense mutations in the control of centrosome duplication.
    • Kais Z, Chiba N, Ishioka C, Parvin JD.
    • Oncogene. 2012 Feb 9;31(6):799-804. doi: 10.1038/onc.2011.271. Epub 2011 Jul 4.
    • Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
    • Aysal A, Karnezis A, Medhi I, Grenert JP, Zaloudek CJ, Rabban JT.
    • Am J Surg Pathol. 2012 Feb;36(2):163-72. doi: 10.1097/PAS.0b013e31823bc434.
    • Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer.
    • Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, Brachtel EF, Schapira L, Come SE, Winer EP, Partridge AH.
    • Breast Cancer Res Treat. 2012 Feb;131(3):1061-6. doi: 10.1007/s10549-011-1872-9. Epub 2011 Nov 13.
    • TLE3 Expression Is Associated with Sensitivity to Taxane Treatment in Ovarian Carcinoma.
    • Samimi G, Ring BZ, Ross DT, Seitz RS, Sutherland RL, O'Brien PM, Hacker NF, Huh WK.
    • Cancer Epidemiol Biomarkers Prev. 2012 Feb;21(2):273-9. doi: 10.1158/1055-9965.EPI-11-0917. Epub 2011 Dec 22.
    • Tetraploidy in BRCA2 breast tumours.
    • Jonsdottir AB, Stefansson OA, Bjornsson J, Jonasson JG, Ogmundsdottir HM, Eyfjord JE.
    • Eur J Cancer. 2012 Feb;48(3):305-10. doi: 10.1016/j.ejca.2011.11.008. Epub 2011 Nov 29.
    • Using tumour pathology to identify people at high genetic risk of breast and colorectal cancers.
    • Hopper JL, Jenkins MA, Dowty JG, Dite GS, Apicella C, Keogh L, Win AK, Young JP, Buchanan D, Walsh MD, Rosty C, Baglietto L, Severi G, Phillips KA, Wong EM, Dobrovic A, Waring P, Winship I, Ramus SJ, Giles GG, Southey MC.
    • Pathology. 2012 Feb;44(2):89-98. doi: 10.1097/PAT.0b013e32834e8e5b.
    • Review
    • Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.
    • Heravi-Moussavi A, Anglesio MS, Cheng SW, Senz J, Yang W, Prentice L, Fejes AP, Chow C, Tone A, Kalloger SE, Hamel N, Roth A, Ha G, Wan AN, Maines-Bandiera S, Salamanca C, Pasini B, Clarke BA, Lee AF, Lee CH, Zhao C, Young RH, Aparicio SA, Sorensen PH, Woo MM, Boyd N, Jones SJ, Hirst M, Marra MA, Gilks B, Shah SP, Foulkes WD, Morin GB, Huntsman DG.
    • N Engl J Med. 2012 Jan 19;366(3):234-42. doi: 10.1056/NEJMoa1102903. Epub 2011 Dec 21.

    Press: Gene Links Rare And Unrelated Cancers. (Medical News Today)

    • BRCAness profile of sporadic ovarian cancer predicts disease recurrence.
    • Wysham WZ, Mhawech-Fauceglia P, Li H, Hays L, Syriac S, Skrepnik T, Wright J, Pande N, Hoatlin M, Pejovic T.
    • PLoS One. 2012;7(1):e30042. doi: 10.1371/journal.pone.0030042. Epub 2012 Jan 11.
    • Dysfunctional telomeres in human BRCA2 mutated breast tumors and cell lines.
    • Bodvarsdottir SK, Steinarsdottir M, Bjarnason H, Eyfjord JE.
    • Mutat Res. 2012 Jan 3;729(1-2):90-9. doi: 10.1016/j.mrfmmm.2011.10.002. Epub 2011 Oct 12.
    • Monozygotic twins discordant for constitutive BRCA1 promoter methylation, childhood cancer and secondary cancer.
    • Galetzka D, Hansmann T, El Hajj N, Weis E, Irmscher B, Ludwig M, Schneider-Rätzke B, Kohlschmidt N, Beyer V, Bartsch O, Zechner U, Spix C, Haaf T.
    • Epigenetics. 2012 Jan 1;7(1):47-54. doi: 10.4161/epi.7.1.18814. Epub 2012 Jan 1.
    • Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
    • Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M, Sherman M, Mulligan AM, Couch FJ, Engel C, McGuffog L, Healey S, Sinilnikova OM, Southey MC, Terry MB, Goldgar D, O'Malley F, John EM, Janavicius R, Tihomirova L, Hansen TV, Nielsen FC, Osorio A, Stavropoulou A, Benítez J, Manoukian S, Peissel B, Barile M, Volorio S, Pasini B, Dolcetti R, Putignano AL, Ottini L, Radice P, Hamann U, Rashid MU, Hogervorst FB, Kriege M, van der Luijt RB; HEBON, Peock S, Frost D, Evans DG, Brewer C, Walker L, Rogers MT, Side LE, Houghton C; EMBRACE, Weaver J, Godwin AK, Schmutzler RK, Wappenschmidt B, Meindl A, Kast K, Arnold N, Niederacher D, Sutter C, Deissler H, Gadzicki D, Preisler-Adams S, Varon-Mateeva R, Schönbuchner I, Gevensleben H, Stoppa-Lyonnet D, Belotti M, Barjhoux L; GEMO Study Collaborators, Isaacs C, Peshkin BN, Caldes T, de la Hoya M, Cañadas C, Heikkinen T, Heikkilä P, Aittomäki K, Blanco I, Lazaro C, Brunet J, Agnarsson BA, Arason A, Barkardottir RB, Dumont M, Simard J, Montagna M, Agata S, D'Andrea E, Yan M, Fox S; kConFab Investigators, Rebbeck TR, Rubinstein W, Tung N, Garber JE, Wang X, Fredericksen Z, Pankratz VS, Lindor NM, Szabo C, Offit K, Sakr R, Gaudet MM, Singer CF, Tea MK, Rappaport C, Mai PL, Greene MH, Sokolenko A, Imyanitov E, Toland AE, Senter L, Sweet K, Thomassen M, Gerdes AM, Kruse T, Caligo M, Aretini P, Rantala J, von Wachenfeld A, Henriksson K; SWE-BRCA Collaborators, Steele L, Neuhausen SL, Nussbaum R, Beattie M, Odunsi K, Sucheston L, Gayther SA, Nathanson K, Gross J, Walsh C, Karlan B, Chenevix-Trench G, Easton DF, Antoniou AC; Consortium of Investigators of Modifiers of BRCA1/2.
    • Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):134-47. doi: 10.1158/1055-9965.EPI-11-0775. Epub 2011 Dec 5.

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: Article Request

    • Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.
    • Vollebergh MA, Jonkers J, Linn SC.
    • Cell Mol Life Sci. 2012 Jan;69(2):223-45. doi: 10.1007/s00018-011-0809-0. Epub 2011 Sep 16.
    • Review
    • Presence of intratumoral stem cells in breast cancer patients with or without BRCA germline mutations.
    • Singer CF, Zabkova P, Rappaport C, Muhr D, Pfeiler G, Gschwantler-Kaulich D, Fink-Retter A, Staudigl C, Walter I, Hudelist G, Spiess AC, Kubista E.
    • Curr Cancer Drug Targets. 2012 Jan;12(1):44-50.
    • [Morphologic and immunohistochemical features of Fallopian tubes and ovaries in women with genetic predisposition to ovarian cancer].
    • Bilyk EA, Buchanskaia LG, Polishchuk LZ, Peëvich T.
    • Vopr Onkol. 2012;58(4):507-13.
    • [Article in Russian]